Is Teva Pharmaceutical Industries (NYSE:TEVA) Still A Bargain Or Fully Priced?

Teva Pharmaceutical Industries has delivered a very strong 5 year share price gain, yet its current valuation picture is split, with an intrinsic value estimate pointing to upside while traditional market multiples lean richer and the broader checks do not flag it as a clear bargain. The stock has also been active on the news front, from fresh clinical data in celiac disease to credit rating upgrades and balance sheet moves, which all feed into how investors think about what that price implies.

• Over the past 5 years, Teva Pharmaceutical Industries has returned about 306%, which puts extra focus on whether today’s price already embeds much of the recovery story.
• Positive trial results for TEV ‘408 in celiac disease and the planned acquisition of neuroscience assets may support expectations for future cash flows, while ongoing financing activity and integration risk around new assets can affect how dependable those cash flows appear.
• On Simply Wall St’s broader checks, Teva scores 2 out of 6 on value, which suggests the shares lean expensive on aggregate even though the Discounted Cash Flow (DCF) estimate screens them as roughly 44% below intrinsic value.

For investors, the debate is whether Teva Pharmaceutical Industries’ current price already reflects the recent re rating and pipeline progress, or whether the Discounted Cash Flow intrinsic value estimate still leaves room for further upside.

Spot opportunities that echo Teva Pharmaceutical Industries’ mix of strong multi year returns and a stretched value score by scanning 31 high quality undervalued stocks. This tool highlights companies that pair robust fundamentals with potential mispricing.

Is Teva Pharmaceutical Industries a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model starts by projecting Teva Pharmaceutical Industries’ future free cash flows and then discounts them back to today. On this view, the key input is current cash generation. Teva’s latest twelve month free cash flow sits at about $1.37b, with analysts and internal estimates assuming that cash flow is growing rather than shrinking over the next decade as the business leans on its existing portfolio and pipeline.

Those assumptions feed into an estimated intrinsic value of about $64.70 per share, which screens as roughly 43.8% above the current share price. Positive Phase 2a data for TEV ‘408 in celiac disease gives that cash flow story more optionality, because progress in this program can support the long term profile the DCF is trying to capture, even if it introduces some execution questions along the way.

On the DCF numbers alone, Teva Pharmaceutical Industries’ stock looks undervalued relative to the cash flows currently built into the model.

Our Discounted Cash Flow (DCF) analysis suggests Teva Pharmaceutical Industries is undervalued by 43.8%. Track this in your watchlist or portfolio, or discover 31 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Teva Pharmaceutical Industries.

Has Teva Pharmaceutical Industries Run Too Far on Earnings?

P/E works well for Teva Pharmaceutical Industries because earnings remain a key yardstick for how the market is weighing its turnaround story and pipeline effort. On this measure, the stock trades at about 60.0x earnings, while the broader pharmaceuticals group sits closer to 16.2x and the selected peer set averages roughly 18.6x. That is a wide gap for a generic and specialty pharma player.

The tailored fair P/E ratio for Teva screens at about 33.8x, which is materially lower than the current 60.0x level. The difference indicates that investors are paying a sizeable premium over what the model suggests would be reasonable given its sector, margins, size and risk profile.

On earnings multiples, Teva Pharmaceutical Industries appears expensive relative to both its industry and the fair P/E benchmark.

See what the numbers say about this price — find out in our valuation breakdown.

The Teva Pharmaceutical Industries Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for Teva Pharmaceutical Industries leaves off by spelling out which future paths for growth, margins and earnings would make the current price look too low or too high on the Community page. Each idea treats fair value as a thesis about Teva Pharmaceutical Industries' business that you can revisit over time, rather than a one off snapshot.

Community views on Teva Pharmaceutical Industries pull in opposite directions, with one side leaning into the pipeline and cost reset while the other worries that execution risk already sits in the price.

Bull case: 13% undervalued

"Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix..."

Read the full Bull Case to see why Teva Pharmaceutical Industries could be undervalued

Bear case: 10% overvalued

"Heavy reliance on a narrow set of growth engines such as AUSTEDO, UZEDY and AJOVY, in indications where underdiagnosis and undertreatment are being actively addressed across the industry, could expose Teva to future competitive launches and reimbursement tightening that may cap pricing power and slow top line expansion..."

Read the full Bear Case to see why Teva Pharmaceutical Industries could be overvalued

Do you think there's more to the story for Teva Pharmaceutical Industries? Head over to our Community to see what others are saying!

The Bottom Line

Teva Pharmaceutical Industries presents a tug-of-war between an intrinsic value estimate that screens as undervalued on Discounted Cash Flow (DCF) and market multiples that flag the shares as overvalued. The split largely comes from the DCF leaning on future cash generation, while the P/E view reflects elevated expectations baked into the price after a very sharp multi year move. Broader valuation checks remain weak, which tempers how much weight you can place on the DCF upside on its own. The real hinge from here is whether Teva can turn its pipeline and portfolio into durable, dependable cash flows rather than a value trap story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com